{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:31:26Z","timestamp":1761093086628,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.urolonc.2017.01.006","type":"journal-article","created":{"date-parts":[[2017,2,8]],"date-time":"2017-02-08T02:15:57Z","timestamp":1486520157000},"page":"432-437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-na\u00efve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide"],"prefix":"10.1016","volume":"35","author":[{"given":"Hideaki","family":"Miyake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuto","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichiro","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2017.01.006_bib1","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2017.01.006_bib2","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.ejca.2014.03.010","article-title":"Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel","volume":"50","author":"Fitzpatrick","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2017.01.006_bib3","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1093\/annonc\/mdv267","article-title":"Treatment of mCRPC in the AR-axis-targeted therapy-resistant state","volume":"26","author":"Chi","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2017.01.006_bib4","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2017.01.006_bib5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2017.01.006_bib6","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2017.01.006_bib7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2017.01.006_bib8","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1464-410X.2009.08345.x","article-title":"Prostate-specific antigen kinetics in localized and advanced prostate cancer","volume":"103","author":"Fitzpatrick","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2017.01.006_bib9","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ctrv.2012.03.008","article-title":"Prostate-specific antigen kinetics as a surrogate endpoint in clinical trials of metastatic castration-resistant prostate cancer: a review","volume":"38","author":"Colloca","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urolonc.2017.01.006_bib10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/pcan.2011.14","article-title":"Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis","volume":"14","author":"Sasaki","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2017.01.006_bib11","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/cncr.24064","article-title":"Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy","volume":"115","author":"Choueiri","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2017.01.006_bib12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00432-014-1612-8","article-title":"Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP)","volume":"140","author":"Kitagawa","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.01.006_bib13","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s12032-013-0719-0","article-title":"Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy","volume":"30","author":"Thomas","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.urolonc.2017.01.006_bib14","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1245\/s10434-014-4105-8","article-title":"Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy","volume":"22","author":"Teoh","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.urolonc.2017.01.006_bib15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4103\/1008-682X.164921","article-title":"Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy","volume":"19","author":"Teoh","year":"2017","journal-title":"Asian J Androl"},{"key":"10.1016\/j.urolonc.2017.01.006_bib16","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1158\/1078-0432.CCR-14-1549","article-title":"Correlation between prostate-specific antigen kinetics and overall survival in abiraterone acetate-treated castration-resistant prostate cancer patients","volume":"21","author":"Xu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2017.01.006_bib17","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.01.006_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2017.01.006_bib19","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2217\/fon.14.24","article-title":"Potential value of rapid prostate-specific antigen decline in identifying primary resistance to abiraterone acetate and enzalutamide","volume":"10","author":"Caffo","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.urolonc.2017.01.006_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.eururo.2014.03.020","article-title":"External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone","volume":"66","author":"Ravi","year":"2014","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814391730008X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814391730008X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:10:49Z","timestamp":1761041449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814391730008X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S107814391730008X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.01.006","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-na\u00efve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}